医学
疾病
重新调整用途
痛风
药品
药物重新定位
关节炎
临床试验
重症监护医学
人口
生物信息学
批准的药物
药理学
免疫学
内科学
生物
生态学
环境卫生
作者
Tiago H. Zaninelli,Geovana Martelossi-Cebinelli,Telma Saraiva‐Santos,Sérgio M. Borghi,Victor Fattori,Rúbia Casagrande,Waldiceu A. Verri
标识
DOI:10.1080/14728222.2023.2247559
摘要
Gout arthritis (GA) is an intermittent inflammatory disease affecting approximately 10% of the worldwide population. Symptomatic phases (acute flares) are timely spaced by asymptomatic periods. During an acute attack, redness, joint swelling, limited movement, and excruciating pain are common symptoms. However, the current available therapies are not fully effective in reducing symptoms and offer numerous side effects. Therefore, unveiling new drug targets and effector molecules are required in developing novel GA therapeutics.This review discusses the pathophysiological mechanisms of GA and explores potential pharmacological targets to ameliorate disease outcome. In addition, we listed promising pre-clinical studies demonstrating effector molecules with therapeutical potential. Among those, we emphasized the importance of natural products, including traditional Chinese medicine formulas and their multitarget mechanisms of action.In our search, we observed that there is a massive gap between pre-clinical and clinical knowledge. Only a minority (4.4%) of clinical trials aimed to intervene by applying natural products or current hot targets described herein. In this sense, we envisage four possibilities for GA therapeutics, which include the repurposing of existing therapies, ALX/FPR2 agonism for improvement in disease outcome, the use of multitarget drugs (e.g. natural products), and targeting the neuroinflammatory component of GA.
科研通智能强力驱动
Strongly Powered by AbleSci AI